SCHEMBL94490

SCHEMBL94490

[CH2]c1ccc(C(=O)N(CC=C)C2CCCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AGER Q15109 3/20 0.45
MTNR1A P48039 1/20 0.45
F2 P00734 3/20 0.44
HSD11B1 P28845 3/20 0.42
ITK Q08881 2/20 0.42
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
SLC6A9 P48067 1/20 0.39
SLC6A5 Q9Y345 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
RECQL P46063 1/20 0.39
ADAM17 P78536 1/20 0.39
PYGL P06737 1/20 0.39
ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL96038 0.81 HSD11B1 (0.62) AGERMTNR1AHSD11B1MEN1KMT2A
SCHEMBL95632 0.76 AGER (0.76) AGERMTNR1AMEN1KMT2ASLC6A9
SCHEMBL95169 0.72 ALDH1A1 (0.58) MEN1KMT2AKDM4ELMNAALOX15
SCHEMBL3178423 0.71 ITK (0.43) F2ITKMEN1KMT2A
SCHEMBL10722280 0.71 HSD11B1 (0.70) AGERMTNR1AHSD11B1MEN1KMT2A
SCHEMBL4486060 0.71 HSD11B1 (0.61) AGERMTNR1AHSD11B1MEN1KMT2A
SCHEMBL15492946 0.71 AGER (0.51) AGERMTNR1AHSD11B1MEN1KMT2A
SCHEMBL5475728 0.71 PYGL (0.39) AGERF2PYGLALDH1A1
SCHEMBL14534797 0.71 F2 (0.40) F2ITKPYGLALDH1A1
SCHEMBL8773489 0.71 ALDH1A1 (0.39) AGERMTNR1AF2PYGLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-7763562-B2 Heteroatom bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2010-07-27 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
US-20070135597-A1 Heteroatom bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. 2007-06-14 US disclosed
WO-2006065809-A2 HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB AGER 3852/4885MTNR1A 1110/4885F2 2751/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 AGER 966/4885MTNR1A 460/4885F2 13/4885
US-20070135597-A1 Heteroatom bridged metallocene compounds for olefin polymerization AP2M1, AP1M1, PYM1 AGER 1466/4885MTNR1A 3719/4885F2 143/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 AGER 966/4885MTNR1A 460/4885F2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.